Sign in to view content

Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2021

Related

Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more